Table 1.

Demographics and baseline kidney function measures for the Cardiovascular Outcomes in Renal Artery Stenosis Trial participants by randomization group

MeasuresStent Plus Medical Therapy, n=459Medical Therapy Only, n=472Difference [95% CI]P Value
Age, yr
 Mean±SD (N)69±9 (459)69±9 (472)0.3 [−0.9 to 1.5]0.60
No. of men51% (234/459)49% (231/472)2 [−4 to 8]0.56
Hispanic or Latino5.2% (24/459)6.6% (31/472)−1.3 [−4.4 to 1.7]0.41
Race0.96
 American Indian or Alaska Native0.2% (1/459)0.2% (1/472)0.0 [−0.6 to 0.6]
 Asian1.1% (5/459)1.5% (7/472)−0.4 [−1.8 to 1.1]
 Black7.0% (32/459)7.0% (33/472)−0.0 [−3.3 to 3.3]
 Native Hawaiian or Pacific Islander0.2% (1/459)0.4% (2/472)−0.2 [−0.9 to 0.5]
 White91.5% (420/459)90.9% (429/472)0.6 [−3.0 to 4.3]
Serum creatinine, mg/dl
 Mean±SD (N)1.26±0.46 (436)1.25±0.47 (454)0.01 [−0.05 to 0.07]0.78
Creatinine-cystatin C CKD-EPI eGFR (ml/min per 1.73 m2)
 Mean±SD (N)59±24 (436)59±23 (454)0.1 [−3.0 to 3.1]0.96
Urine albumin-to-creatinine ratio, mg/g
 Median (IQR)24 (10–98.0)21 (9–75)2 [−4 to 8]0.29
CKD stage ≥360% (261/436)58% (265/454)−3 [−10 to 3]0.47
  • P values for comparisons are generated with two–sample t tests for continuous measurements and chi-squared tests for binary measurements. 95% CI, 95% confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; IQR, interquartile range.